Sapropterin Dipharma: Uses, Dosage & Side Effects
Tetrahydrobiopterin (BH4) cofactor — Reduces blood phenylalanine in responsive phenylketonuria (PKU)
Quick Facts About Sapropterin Dipharma
Key Takeaways About Sapropterin Dipharma
- Generic equivalent of Kuvan: Sapropterin Dipharma contains the same active ingredient (sapropterin dihydrochloride 100 mg) as Kuvan. Bioequivalence has been established through EMA-approved assessment, so clinical efficacy and safety are considered equivalent
- Only for responsive patients: Treatment benefit is limited to individuals whose blood phenylalanine falls meaningfully during a defined responsiveness trial. Patients with classical PKU and no responsiveness should not continue long-term therapy
- Diet remains essential: Sapropterin Dipharma is not a cure and does not replace the phenylalanine-restricted diet. It may, however, significantly increase the amount of natural protein that a responsive patient can safely tolerate
- Take once daily with food: Dissolve the prescribed number of 100 mg tablets in water and drink within 15–30 minutes. Taking with a meal improves absorption by roughly 40–85% compared with the fasted state
- Monitor blood phenylalanine closely: Blood phenylalanine should be checked 1 to 2 weeks after starting or adjusting the dose, and then at regular intervals as directed by your metabolic team. Very low phenylalanine can be as harmful as high phenylalanine, particularly in children
What Is Sapropterin Dipharma and What Is It Used For?
Sapropterin Dipharma contains sapropterin dihydrochloride, a synthetic form of 6R-tetrahydrobiopterin (6R-BH4). BH4 is the natural cofactor for the enzyme phenylalanine hydroxylase, which converts the amino acid phenylalanine into tyrosine. In people with a BH4-responsive form of phenylketonuria (PKU), supplying extra BH4 stabilises the residual enzyme and helps normal phenylalanine metabolism, lowering blood phenylalanine and reducing the risk of neurological complications.
Sapropterin Dipharma is a prescription-only medicine manufactured as a generic version of Kuvan. The active substance, sapropterin dihydrochloride, is identical at the molecular level to the natural cofactor tetrahydrobiopterin (BH4) that is produced in the human body. BH4 is indispensable for a small number of critical enzymes, including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, tryptophan hydroxylase, and nitric oxide synthase. When these enzymes cannot function normally — because of genetic changes in the enzymes themselves or in the BH4 synthesis/regeneration pathway — neurotoxic metabolites accumulate and neurotransmitter production is compromised.
Phenylketonuria (PKU) is the most common inherited disorder of amino acid metabolism. It is caused by mutations in the PAH gene on chromosome 12, which codes for the enzyme phenylalanine hydroxylase. The global incidence is approximately 1 in 10,000 live births, with significant variation between populations (up to 1 in 4,500 in some European countries and 1 in 125,000 in parts of East Asia). Without treatment, accumulated phenylalanine damages the developing brain, causing severe intellectual disability, microcephaly, seizures, and behavioural disturbances. Thanks to universal newborn screening programmes, most children with PKU are now diagnosed in the first week of life and started on a phenylalanine-restricted diet immediately, which in most cases prevents these catastrophic outcomes.
BH4-responsive PKU is a subtype in which residual PAH enzyme activity can be pharmacologically enhanced by giving additional BH4. The degree of responsiveness varies with genotype: most people with mild PKU or non-PKU hyperphenylalaninemia are responsive, while the majority with classical PKU (blood phenylalanine above 1,200 µmol/L at diagnosis) are not. Sapropterin Dipharma therefore does not replace dietary management but, in selected patients, can substantially improve metabolic control and quality of life. Clinical trials, including the pivotal PKU-003 and PKU-004 studies, demonstrated that responsive adults and children can achieve meaningful reductions in blood phenylalanine (roughly 30–40% on average) while increasing their natural protein tolerance.
Sapropterin Dipharma is also approved for patients with tetrahydrobiopterin (BH4) deficiency, a rare group of inherited disorders affecting BH4 biosynthesis or regeneration. In these conditions, the PAH enzyme itself is normal, but the missing cofactor prevents phenylalanine metabolism and also impairs the production of dopamine and serotonin. BH4 deficiency is less common than PKU and is classified according to the specific enzyme involved (PTPS deficiency, GTPCH deficiency, DHPR deficiency, or PCD deficiency). Treatment in these patients typically combines sapropterin with neurotransmitter precursors, such as levodopa/carbidopa and 5-hydroxytryptophan.
Approved Indications
Sapropterin Dipharma is approved for the following clinical indications in adults and paediatric patients from birth:
- Hyperphenylalaninemia (HPA) in phenylketonuria (PKU): For adults and children from birth who have been shown to be responsive to tetrahydrobiopterin treatment. The medicine is used alongside an individualised phenylalanine-restricted diet and regular blood phenylalanine monitoring to maintain safe phenylalanine concentrations.
- Tetrahydrobiopterin (BH4) deficiency: For adults and children from birth with documented BH4 deficiency and residual PAH enzyme activity. In these rarer disorders, sapropterin supplies the missing cofactor and is often combined with additional therapies targeting dopamine and serotonin pathways.
Sapropterin is the synthetic, pharmaceutical-grade form of the active (6R)-isomer of tetrahydrobiopterin. Tetrahydrobiopterin is the obligate cofactor of phenylalanine hydroxylase: it supplies the electrons and active-site geometry needed for the enzyme to insert an oxygen atom into phenylalanine, producing tyrosine. In BH4-responsive PKU, residual enzyme is present but unstable or poorly active at physiological BH4 concentrations. By providing supraphysiological amounts of BH4, sapropterin acts as a chemical chaperone that stabilises the enzyme, shifts it toward its active conformation, and enhances catalytic turnover. In BH4 deficiency, the mechanism is simpler: sapropterin directly replaces the missing cofactor.
Generic Equivalence and Quality Assurance
As a generic medicine, Sapropterin Dipharma has undergone regulatory assessment by the European Medicines Agency, based on demonstration of bioequivalence to the originator product Kuvan. Bioequivalence studies confirm that the generic formulation delivers the same systemic exposure to sapropterin — measured by area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cmax) — as the reference product. EMA requirements stipulate that the 90% confidence interval of the ratio of these parameters falls within the accepted 80–125% range, ensuring therapeutic equivalence.
Dipharma Francis S.r.l., part of the Dipharma group, is a European pharmaceutical manufacturer that develops and supplies active pharmaceutical ingredients and finished products under Good Manufacturing Practice (GMP) standards. As with all EMA-authorised generics, Sapropterin Dipharma is produced to the same quality, purity, and potency standards as the originator product. Patients switching between Kuvan and Sapropterin Dipharma should not experience any clinically meaningful change in efficacy or tolerability, although individual metabolic teams may monitor blood phenylalanine more closely around a brand change as a precaution.
The Role of BH4 Responsiveness Testing
Before committing to long-term sapropterin therapy, patients must undergo a BH4 responsiveness test, because only a fraction of people with PKU will benefit. Testing protocols vary between metabolic centres, but typically involve giving sapropterin at 20 mg per kilogram once daily for one to four weeks while monitoring blood phenylalanine at frequent intervals. A response is usually defined as a reduction in blood phenylalanine of at least 30% from baseline, although some centres use different thresholds or outcomes (for example, tolerance of a defined phenylalanine load or improvement of symptoms in BH4 deficiency).
Genotyping can help predict responsiveness. Certain PAH mutations — such as those preserving partial enzyme function (missense mutations in non-catalytic domains) — are more commonly associated with responsiveness, while null mutations (frameshift, large deletions, or nonsense variants affecting both alleles) predict non-responsiveness. However, genotype alone is not sufficient to determine eligibility, and a biochemical trial is recommended in all potentially suitable patients. Long-term follow-up is then required to confirm sustained benefit and guide dietary liberalisation.
What Should You Know Before Taking Sapropterin Dipharma?
Before starting Sapropterin Dipharma, your metabolic specialist will confirm BH4 responsiveness, review your current phenylalanine intake, and screen for conditions that could affect safety. It should not be used by people with known hypersensitivity to sapropterin, and caution is required during pregnancy, breastfeeding, seizure disorders, and in patients taking certain interacting medicines. Blood phenylalanine must be monitored closely throughout treatment.
Sapropterin Dipharma is a specialised treatment that must be prescribed and monitored by a physician experienced in the management of PKU or BH4 deficiency, usually within a designated inherited metabolic disease (IMD) centre. A thorough pretreatment evaluation helps identify patients most likely to benefit, sets realistic expectations, and minimises the risk of side effects or preventable complications. The following considerations should be discussed with your treating team before you begin therapy.
Contraindications
You should not take Sapropterin Dipharma if any of the following apply:
- Hypersensitivity to sapropterin: People with a documented allergy to sapropterin dihydrochloride or to any of the excipients in the formulation (including mannitol, ascorbic acid, sodium stearyl fumarate, crospovidone, and the riboflavin colouring agent) must not take this medicine.
- Confirmed non-responsiveness: Sapropterin provides no benefit in patients whose blood phenylalanine does not fall during an adequately conducted responsiveness trial. Continuing therapy in a non-responder exposes the patient to side effects and cost without any therapeutic gain.
There are no absolute age-related contraindications — sapropterin can be used from birth in responsive patients — and no absolute restrictions based on kidney or liver function, although caution is warranted in specific situations as outlined below.
Warnings and Precautions
Discuss the following conditions with your metabolic specialist before starting Sapropterin Dipharma. They do not necessarily preclude treatment, but they may require closer monitoring, dose adjustment, or additional supportive measures.
- Sudden swelling of the face, lips, tongue, or throat, or difficulty breathing — possible severe allergic reaction
- A widespread rash, especially with blistering, peeling skin, fever, or mouth ulcers
- New or worsening seizures, especially if you have a known seizure disorder
- Severe or persistent vomiting, diarrhoea, abdominal pain, or refusal to eat in a child
- Low blood phenylalanine (hypo-phenylalaninemia): Sapropterin can lower blood phenylalanine below the target range if dietary protein is not simultaneously increased. Phenylalanine is an essential amino acid needed for growth, neurotransmitter precursor production, and normal development. Very low concentrations (below 30 µmol/L for prolonged periods) are associated with reduced growth and poor neurodevelopmental outcomes in infants. Your team will adjust dietary phenylalanine tolerance alongside the medicine.
- Seizure disorders: Sapropterin has occasionally been associated with exacerbation of convulsive disorders, particularly in patients with preexisting epilepsy or BH4 deficiency. Patients with seizure disorders should be closely monitored, and antiepileptic therapy optimised before and during treatment.
- Intercurrent illness: Illnesses that increase catabolism — such as fever, vomiting, or surgery — can transiently raise blood phenylalanine. Contact your metabolic team promptly during intercurrent illness, as dose or dietary adjustments may be needed.
- Medications that affect BH4 metabolism: Drugs that inhibit dihydrofolate reductase (such as methotrexate and trimethoprim) can potentially affect BH4 regeneration and should be used with caution. PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil) and nitric oxide donors may have pharmacodynamic interactions — see the Interactions section below.
- Renal impairment: There is limited experience with sapropterin in patients with severe renal impairment. Close clinical monitoring is recommended in this group. Hepatic impairment has not been shown to require dose adjustment, but data are limited.
- Gastric acid suppression: Sapropterin absorption is pH-dependent. In theory, strong gastric acid suppression with proton pump inhibitors may reduce absorption, although clinical studies have not shown a consistent effect. If you regularly take antacids or acid-suppressing drugs, inform your metabolic team so that blood phenylalanine can be reassessed.
Blood Phenylalanine Monitoring Schedule
Effective sapropterin therapy depends on precise monitoring of blood phenylalanine concentrations. A typical schedule, adapted from European PKU guidelines, is summarised below:
- Before treatment initiation: baseline blood phenylalanine, tyrosine, and full dietary assessment
- Responsiveness test: blood phenylalanine at baseline, then at 24 hours, 1 week, 2 weeks, and 4 weeks while taking 20 mg/kg once daily
- During dose finding: blood phenylalanine every 1 to 2 weeks until stable, then monthly
- Chronic therapy: at least monthly in infants and young children; every 1 to 3 months in adolescents and adults, depending on metabolic stability
- During pregnancy planning and pregnancy: much more intensive monitoring (often weekly) in consultation with a maternal PKU specialist
- During intercurrent illness: additional unscheduled measurements as clinically indicated
Pregnancy, Breastfeeding, and Fertility
Maternal PKU syndrome is a well-documented risk: uncontrolled high maternal phenylalanine during pregnancy is severely teratogenic, causing microcephaly, congenital heart disease, intrauterine growth restriction, and intellectual disability in the child, regardless of whether the child has inherited PKU. Therefore, strict metabolic control during pregnancy is essential for all women with PKU, and preconception planning with a maternal PKU clinic is strongly recommended.
Animal studies have not shown evidence of direct teratogenicity from sapropterin itself, and clinical experience in pregnancy is steadily growing. However, safety in pregnancy has not been definitively established. Sapropterin may be considered during pregnancy in responsive women when the benefit of improved phenylalanine control outweighs any theoretical risk — particularly when dietary management alone cannot maintain target blood phenylalanine levels (typically 120–360 µmol/L throughout pregnancy). This decision must be made in collaboration with a specialist maternal PKU team.
It is not known whether sapropterin is excreted in human breast milk. A cautious individual risk-benefit assessment, considering both maternal metabolic control and the infant's possible exposure, should guide decisions about breastfeeding while on sapropterin. There is no evidence that sapropterin impairs male or female fertility.
Use in Specific Populations
Sapropterin Dipharma is approved from birth and is widely used in paediatric practice. In neonates and infants, particular care is taken to avoid over-correction of blood phenylalanine, because phenylalanine is an essential amino acid and undersupply can harm growth and brain development. Safe and effective use in elderly adults (aged 65 years and above) has not been specifically studied; however, no dose adjustment is generally required for age alone, and standard monitoring applies.
Driving and Operating Machinery
Sapropterin Dipharma is not expected to impair the ability to drive or operate machinery. Some patients may experience mild headache or dizziness, particularly when starting treatment; if this occurs, wait until symptoms resolve before driving. Very low blood phenylalanine, if it occurs, can cause fatigue and poor concentration, so any impairment in alertness should prompt a blood phenylalanine check and dietary review.
Important Information About Excipients
Sapropterin Dipharma soluble tablets contain mannitol (may have a mild laxative effect) and small amounts of sodium. The formulation is gluten-free and lactose-free. Patients who need to follow a sodium-controlled diet should note the exact sodium content listed on the current package leaflet, although the total dose per day is considered negligible for most patients.
How Does Sapropterin Dipharma Interact with Other Drugs?
Sapropterin can interact with several medicines that affect BH4 metabolism or nitric oxide signalling. Important interactions include levodopa (risk of neurological side effects), methotrexate and trimethoprim (reduced BH4 recycling), and PDE5 inhibitors or nitric oxide donors (additive vasodilation). Always tell your doctor and pharmacist about every prescription medicine, over-the-counter product, vitamin, and herbal supplement you take.
Interactions with sapropterin can be grouped by mechanism: drugs that interfere with BH4 synthesis or regeneration, drugs that modify dopaminergic pathways, and drugs that share downstream effects on the nitric oxide system. Because sapropterin is taken long-term, it is important to review potential interactions whenever a new medicine is started, not only at the time of initial prescription. Generic Sapropterin Dipharma shares the same interaction profile as Kuvan and other sapropterin dihydrochloride products.
Always inform your metabolic team and your pharmacist about all other medicines you take, including occasional over-the-counter purchases and herbal or dietary supplements. Many health problems can be safely treated while on sapropterin, provided interactions are considered in advance.
Major Interactions
The following interactions are clinically significant and may require dose adjustment, closer monitoring, or in some cases, alternative therapy:
| Drug / Class | Interaction Mechanism | Clinical Action |
|---|---|---|
| Levodopa (often with carbidopa or benserazide) | Sapropterin increases central BH4, which can enhance levodopa's effect and raise the risk of dyskinesia, agitation, or irritability, particularly in patients with BH4 deficiency | Introduce sapropterin cautiously; adjust levodopa dose as needed; monitor for neurological side effects |
| Methotrexate | Inhibits dihydrofolate reductase, a key enzyme in BH4 regeneration, potentially reducing endogenous BH4 recycling | Use with caution; closer blood phenylalanine monitoring; consider dose timing and clinical review |
| Trimethoprim (including co-trimoxazole) | Weak inhibition of dihydrofolate reductase; theoretical reduction in BH4 regeneration with prolonged use | Short courses usually acceptable; monitor blood phenylalanine if prolonged therapy is needed |
| PDE5 inhibitors (sildenafil, tadalafil, vardenafil) | BH4 is the cofactor for nitric oxide synthase; additive effects on vascular smooth muscle relaxation may cause hypotension | Use together with caution; monitor blood pressure; patient counselling about possible hypotension |
| Nitric oxide donors (glyceryl trinitrate, isosorbide mononitrate, sodium nitroprusside) | Additive vasodilation; possible enhanced hypotensive effect | Use with caution; careful blood pressure monitoring, particularly in elderly or cardiovascular patients |
| Pegvaliase (phenylalanine ammonia-lyase) | Both agents lower blood phenylalanine; combined use rarely clinically indicated and may produce excessive phenylalanine reduction | Concurrent use is not recommended without specialist review of indication and metabolic targets |
Other Notable Interactions
Beyond the major interactions above, a number of drugs can affect BH4 handling or overlap with sapropterin's downstream effects. These are usually manageable with awareness and routine monitoring:
| Drug | Effect | Action Required |
|---|---|---|
| Folic acid and folate supplements | Generally compatible; adequate folate supports BH4 recycling | Continue as prescribed; no dose change needed |
| Proton pump inhibitors (omeprazole, pantoprazole) | Theoretical reduction in sapropterin absorption due to altered gastric pH | Inform metabolic team; monitor blood phenylalanine after initiation |
| Corticosteroids (high-dose, long-term) | May increase protein catabolism and blood phenylalanine | Monitor blood phenylalanine; adjust diet or dose during steroid courses |
| Neurotransmitter precursors (5-HTP, L-DOPA) in BH4 deficiency | Often co-prescribed; require careful dose titration | Managed by metabolic/neurology team; follow individualised protocol |
| Aspartame-containing products | Aspartame releases phenylalanine during digestion, raising blood phenylalanine | Avoid aspartame-containing drinks, sweeteners, and medicines; check excipients |
| Vaccines | No specific interaction; routine immunisations are safe and encouraged | Follow national immunisation schedule; monitor blood phenylalanine during febrile illness |
Sapropterin Dipharma is absorbed more efficiently when taken with food. Clinical pharmacology studies show that a meal increases AUC by roughly 40–85% compared with the fasted state. For consistency, the dose should be taken at the same time of day with a meal, typically in the morning. The number of tablets prescribed should be dissolved in 120–240 mL of water (80–120 mL for children under 20 kg) within 15 minutes before the dose and drunk within the following 15 minutes. Orange juice, apple juice, or water can be used if plain water is not tolerated, but do not use milk or carbonated beverages.
What Is the Correct Dosage of Sapropterin Dipharma?
The usual starting dose is 10 mg per kilogram of body weight once daily, taken with a meal. Based on the blood phenylalanine response, the dose may be titrated between 5 and 20 mg per kilogram per day. Dissolve the prescribed number of 100 mg tablets in a small amount of water and drink within 15–30 minutes. Never exceed 20 mg/kg per day without specialist instruction.
Dosing of Sapropterin Dipharma is individualised and must be determined by a physician experienced in the management of PKU or BH4 deficiency. Dose is based on body weight, metabolic response, age, and the specific diagnosis. The prescription is always part of a broader management plan that includes dietary phenylalanine control and regular laboratory monitoring. Deviations from prescribed dosing — particularly skipping doses or taking the medicine without food — can result in unpredictable blood phenylalanine levels.
Adults and Adolescents (aged 12 years and above)
| Indication | Dose | Instructions |
|---|---|---|
| PKU — responsiveness test | 20 mg/kg once daily for 1–4 weeks | Measure blood phenylalanine at baseline and weekly; continue only if ≥30% reduction |
| PKU — maintenance | Typically 10 mg/kg once daily (range 5–20 mg/kg/day) | Titrate to maintain blood phenylalanine within individualised target range; take with a meal |
| BH4 deficiency | 2–5 mg/kg once daily initially (up to 20 mg/kg in selected cases) | Adjust based on blood phenylalanine, neurotransmitter markers, and clinical response |
| Maximum dose | 20 mg/kg/day | Do not exceed unless specifically advised by a metabolic specialist |
How to Take Sapropterin Dipharma
Correct preparation and administration are essential for consistent, reliable drug exposure:
- Once-daily dosing: Take the prescribed dose once a day, preferably in the morning at the same time each day, to maintain steady blood levels.
- With a meal: Take with or immediately after food. Food significantly increases absorption; taking doses consistently fasted leads to lower and more variable drug exposure.
- Dissolve in water: Place the prescribed number of 100 mg tablets in a glass of water — 120 to 240 mL for adults and children weighing 20 kg or more, or 80 to 120 mL for smaller children. Stir gently until the tablets have dissolved (this may take up to 15 minutes; some small particles may remain).
- Drink promptly: Drink the full solution within 15–30 minutes of preparation. If any residue remains in the glass, add a small amount of additional water, swirl, and drink to ensure the full dose is taken.
- Tablet count: Doses are calculated to the nearest 100 mg, which sometimes requires rounding. Your pharmacist will explain exactly how many tablets to take based on your weight.
- Do not chew or swallow whole: The tablets are formulated for dissolution; swallowing whole may reduce absorption.
Children (from birth to 11 years)
Paediatric Dosing
- Infants and young children: The starting dose is usually 10 mg/kg once daily. Because small children may find it difficult to drink a full adult-sized solution, the total volume of water used to dissolve the tablets can be reduced to 80–120 mL while keeping the full prescribed dose.
- Accurate dosing: For very small children, where the prescribed dose is less than 100 mg, the pharmacist will provide specific instructions (for example, dissolving one tablet and taking only a measured fraction using an oral syringe).
- Dose adjustment with growth: As the child gains weight, the dose must be recalculated and adjusted periodically to maintain mg/kg targets.
- Monitoring: Blood phenylalanine is typically checked every 1 to 4 weeks in infants and young children, with more frequent measurements during intercurrent illness.
Elderly Patients
Limited clinical trial data are available in patients aged 65 years and older, as PKU is primarily diagnosed and treated in childhood. No routine dose adjustment is recommended for age alone. However, elderly patients are more likely to have age-related renal or hepatic impairment, concomitant medications, and cardiovascular conditions that could modify risk. Standard clinical monitoring and individual dose titration are therefore appropriate.
Patients with Renal or Hepatic Impairment
Limited pharmacokinetic data are available in patients with severe renal or hepatic impairment. Sapropterin and its metabolites are partially excreted by the kidneys. In practice, cautious dose titration with blood phenylalanine monitoring is used rather than prespecified renal or hepatic dose adjustments. If you have significant liver or kidney disease, discuss individualised dosing with your metabolic team.
Missed Dose
If you forget to take Sapropterin Dipharma, take the missed dose as soon as you remember on the same day, preferably with food. If it is already close to the time of your next scheduled dose, skip the missed dose and continue with your usual schedule. Do not take a double dose to make up for a missed one, as this can transiently lower blood phenylalanine more than intended. If you forget multiple doses in a row, contact your metabolic team, as additional blood phenylalanine checks may be needed.
Overdose
If a larger-than-prescribed dose is taken, contact your metabolic specialist, local poison control centre, or hospital emergency department for advice. Reported overdoses with sapropterin have generally been well tolerated, with the most common symptoms being headache and dizziness. Treatment is supportive. Bring the medication package to the hospital so that the exact product, strength, and amount ingested can be identified, and blood phenylalanine may be checked.
Do not stop Sapropterin Dipharma abruptly, particularly if you have liberalised your diet based on its effect. Discontinuing the medicine without simultaneously reducing natural protein intake will cause blood phenylalanine levels to rise sharply, which can be harmful to brain function. Any change in therapy — including dose reduction, switching brands, or planned discontinuation — should be coordinated with your metabolic team and accompanied by close blood phenylalanine monitoring.
What Are the Side Effects of Sapropterin Dipharma?
Like all medicines, Sapropterin Dipharma can cause side effects, but many people take it without problems. The most common side effects are headache and runny nose. Other common effects include sore throat, cough, nasal congestion, stomach upset, and transient low blood phenylalanine. Serious side effects, such as severe allergic reactions, are rare but require immediate medical attention.
The side effect profile of sapropterin has been characterised in several clinical trials, including PKU-003, PKU-004, and PKU-006, and confirmed through more than 15 years of post-marketing experience with the originator product. Most side effects are mild to moderate, transient, and occur more commonly during the first weeks of treatment as the body adapts to the new therapy. The profile is considered equivalent for the generic Sapropterin Dipharma, given demonstrated bioequivalence.
Report all suspected side effects to your metabolic team, even when they seem minor. Many reactions resolve spontaneously or respond to simple measures such as taking the dose with a different meal, adjusting the amount of water used for dissolution, or changing the time of day.
- Sudden swelling of the face, lips, tongue, or throat, hives, difficulty swallowing, or severe difficulty breathing — signs of a severe allergic reaction (anaphylaxis)
- Widespread blistering rash, skin peeling, high fever, or mouth ulcers — possible severe cutaneous reaction
- New or markedly worsened seizures
- Severe or persistent vomiting, dehydration, or refusal to eat in an infant or young child
Very Common Side Effects
- Headache
- Runny nose (rhinorrhea)
Common Side Effects
- Sore throat (pharyngolaryngeal pain)
- Nasal congestion
- Cough
- Diarrhoea
- Vomiting
- Abdominal pain
- Low blood phenylalanine (hypo-phenylalaninemia)
Uncommon Side Effects
- Gastritis and other upper gastrointestinal discomfort
- Oesophageal irritation
- Dizziness
- Hypersensitivity reactions (rash, itching)
Rare Side Effects
- Severe hypersensitivity reactions, including anaphylaxis
Frequency Not Known
- Exacerbation of seizures in patients with preexisting seizure disorders
- Irritability, particularly when used with levodopa in BH4 deficiency
- Reduced appetite
Managing Common Side Effects
Most mild side effects can be managed without stopping treatment. Practical measures include:
- Headache: Usually occurs in the first weeks and resolves spontaneously. Stay well hydrated, take the dose with a full meal, and discuss simple analgesics with your pharmacist if needed.
- Upper respiratory symptoms: Runny nose, nasal congestion, sore throat, and cough are often reported in clinical trials. They may reflect coincidental viral infections rather than true drug effects. Standard symptomatic care is appropriate.
- Gastrointestinal symptoms: Taking the medicine with food, adjusting the volume of water used, or changing the type of meal (more neutral flavours, avoiding very fatty foods) can help. Persistent vomiting or diarrhoea requires medical review, as it may cause dehydration and destabilise metabolic control.
- Low blood phenylalanine: If blood phenylalanine drops below the recommended range, your metabolic dietitian will guide an increase in natural protein intake or a temporary dose reduction.
If you experience any side effects, including those not listed above, report them to your metabolic team. You can also report side effects directly to your national pharmacovigilance authority — for example, the FDA MedWatch programme in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA EudraVigilance system in the European Union. Reporting helps maintain ongoing safety surveillance for all sapropterin products, including generics such as Sapropterin Dipharma.
How Should You Store Sapropterin Dipharma?
Store Sapropterin Dipharma in its original bottle, tightly closed, at or below 25°C (77°F), protected from moisture. Keep the desiccant in the bottle. Do not transfer tablets to other containers. Always keep out of sight and reach of children, and do not use after the expiration date.
Proper storage is essential to maintain the potency and stability of Sapropterin Dipharma soluble tablets. Sapropterin is sensitive to moisture and, to a lesser extent, to heat and light. The bottle is designed with these properties in mind and usually contains a desiccant packet to protect the tablets.
- Temperature: Store at or below 25°C (77°F). Do not refrigerate or freeze, unless specifically directed by the current product leaflet, as cold storage can promote moisture condensation inside the bottle.
- Packaging: Keep the tablets in the original bottle, tightly closed, to protect them from moisture and light. Leave the desiccant packet inside the bottle. Do not transfer tablets to pill organisers, blister cards, or other containers.
- Children: Keep out of sight and reach of children. Although acute overdose is generally well tolerated, medicines should always be stored safely.
- Expiration: Do not use Sapropterin Dipharma after the expiration date printed on the bottle and carton (marked "EXP"). The expiration date refers to the last day of the indicated month.
- Disposal: Do not dispose of medicines via household waste or wastewater. Return any unused or expired tablets to your pharmacy for proper disposal. This protects the environment and prevents accidental ingestion.
- After opening: Refer to the current leaflet for the in-use shelf life once the bottle is opened, and always observe any specific handling instructions provided by your pharmacist.
What Does Sapropterin Dipharma Contain?
Each Sapropterin Dipharma soluble tablet contains 100 mg of sapropterin dihydrochloride as the active ingredient. Inactive ingredients include mannitol, ascorbic acid, sodium stearyl fumarate, crospovidone, and a riboflavin colouring agent. The tablets are gluten-free and lactose-free and are intended for dissolution in water before oral administration.
Understanding the composition of Sapropterin Dipharma helps identify potential allergens or intolerances and provides useful information when discussing treatment with pharmacists and dietitians. The formulation is designed to dissolve efficiently in water to produce a pale yellow solution that is easier to take than a swallowed tablet, particularly in young children.
Active Ingredient
The active substance is sapropterin dihydrochloride. Each soluble tablet contains 100 mg of sapropterin dihydrochloride, corresponding to approximately 77 mg of sapropterin base. Sapropterin dihydrochloride is the synthetic pharmaceutical-grade form of the naturally occurring cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin, which serves as the essential cofactor for phenylalanine hydroxylase and several related enzymes.
Excipients (Inactive Ingredients)
The other ingredients in Sapropterin Dipharma 100 mg soluble tablets typically include:
- Tablet core: Mannitol (a sugar alcohol that also acts as a sweetener and bulking agent), ascorbic acid (vitamin C, which stabilises the active ingredient by preventing oxidation), sodium stearyl fumarate (a lubricant), crospovidone (a disintegrant that helps the tablet dissolve rapidly), and riboflavin (E101, a yellow-orange colouring agent).
Patients should check the current package leaflet for the exact list of excipients, as formulations may be updated over time. The medicine is free from gluten and lactose. If you have known intolerances to any excipient, discuss this with your pharmacist before starting therapy.
Appearance and Pack Sizes
Sapropterin Dipharma 100 mg soluble tablets are off-white to light yellow tablets, supplied in HDPE bottles containing typically 30 or 120 tablets with a child-resistant closure and a desiccant packet. Pack sizes may vary by country; not all pack sizes may be marketed. Check the bottle carefully on dispensing to confirm you have received the expected strength and quantity.
Marketing Authorization Holder
Dipharma Francis S.r.l., Via Bissone 5, 20021 Baranzate (MI), Italy. Dipharma operates under European Union Good Manufacturing Practice (GMP) standards and supplies sapropterin dihydrochloride to markets across the European Economic Area and, through partners, in other regions. For the most current authorisation details in your country, consult the package leaflet or your national medicines regulator.
Frequently Asked Questions About Sapropterin Dipharma
Medical References
All medical information in this article is based on peer-reviewed research, international clinical guidelines, and official drug regulatory documentation. Evidence level: 1A (systematic reviews and meta-analyses of randomized controlled trials).
- European Medicines Agency (EMA). "Sapropterin Dipharma — Summary of Product Characteristics (SmPC)." EMA Official European regulatory documentation for Sapropterin Dipharma (sapropterin dihydrochloride).
- U.S. Food and Drug Administration (FDA). "Kuvan (sapropterin dihydrochloride) — Prescribing Information." FDA FDA-approved labeling and safety information for the originator sapropterin product.
- Levy HL, et al. (2007). "Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study." The Lancet. 370(9586):504–510. doi:10.1016/S0140-6736(07)61234-3 Pivotal PKU-003 trial establishing efficacy of sapropterin in BH4-responsive PKU.
- Trefz FK, et al. (2009). "Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study." Journal of Pediatrics. 154(5):700–707. doi:10.1016/j.jpeds.2008.11.040 PKU-006 study demonstrating improved natural protein tolerance in paediatric patients.
- van Spronsen FJ, et al. (2017). "Key European guidelines for the diagnosis and management of patients with phenylketonuria." The Lancet Diabetes & Endocrinology. 5(9):743–756. doi:10.1016/S2213-8587(16)30320-5 European guidelines on the diagnosis and management of PKU, including sapropterin use.
- Blau N, et al. (2010). "Management of phenylketonuria in Europe: survey results from 19 countries." Molecular Genetics and Metabolism. 99(2):109–115. doi:10.1016/j.ymgme.2009.09.005 European survey on PKU management, including BH4 responsiveness testing practice.
- Opladen T, et al. (2020). "Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies." Orphanet Journal of Rare Diseases. 15(1):126. doi:10.1186/s13023-020-01379-8 International consensus guideline for diagnosis and treatment of BH4 deficiencies.
- World Health Organization (WHO). "Newborn screening for phenylketonuria and congenital hypothyroidism." WHO WHO recommendations on newborn screening, including PKU detection and early treatment.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in metabolic medicine, paediatrics, and clinical pharmacology
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic backgrounds and clinical experience. Our editorial team for this article includes:
Metabolic Specialists
Licensed physicians specialising in inherited metabolic disorders, with documented experience in the management of PKU and BH4 deficiencies across the lifespan.
Clinical Pharmacologists
Experts in clinical pharmacology with extensive knowledge of drug interactions, pharmacokinetics, and evidence-based prescribing in paediatric metabolic medicine.
Metabolic Dietitians
Registered dietitians specialising in low-phenylalanine diets, natural protein tolerance assessment, and nutrition management across paediatric and adult PKU care.
Medical Review
Independent review panel that verifies all content against European and international PKU guidelines, EMA and FDA labelling, and current peer-reviewed research.
Qualifications and Credentials
- Licensed specialist physicians with recognised specialist competence
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO, EMA, and European PKU guidelines
- Adherence to the GRADE framework for evidence-based medicine
- No conflicts of interest or pharmaceutical industry funding
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer reviews before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in metabolic medicine, paediatrics, pharmacology, internal medicine, and clinical research.